Expansion of the Product Lineup in Hematology, Coagulation and Urinalysis

「Finally, we launched the HISCL™ HIT IgG Reagent in the domestic market on 27 September 2024. The reagent measures IgG antibodies against complexes of platelet factor 4 and heparin.」

「March 2024: We began domestic sales of 6 immunoassay panels for gynecology and sex hormones: HISCL LH Reagent, HISCL FSH Reagent, HISCL Prolactin Reagent, HISCL Estradiol Reagent, HISCL Progesterone Reagent and HISCL Testosterone Reagent.」

「Against this backdrop, following launches in overseas regions, we launched in Japan a clinical flow cytometry system combining the XF-1600 flow cytometer and PS-10 sample preparation system, together with related products including antibody reagents.」

「We have established priority actions to pursue over the next 3 years and will continue implementing specific measures. In addition to hematology, the group's largest source of earnings, we have designated blood coagulation testing, immunoassay and life sciences as priority fields. By allocating resources preferentially, we will strengthen research and development activities, create new value and expand our product lineup.」

「④ July 2022: We launched the new sample transportation system product range compatible with the XR™ Series flagship hematology analyzers: the BT-50 barcode terminal, TS-01 sample sorting system and TA-01 sample storage system.」

「Against this backdrop, we launched a new range of sample transportation system products compatible with the next-generation flagship XR™ Series of hematology analyzers. In addition to the world's first automated measurement function for quality control materials installed in a hematology instrument, the modules provide functions including automatic sample sorting, sample storage and transport of cleaning materials, enabling further automation and efficiency improvements in laboratory operations.」

「We launched the next-generation flagship XR Series of automated multi-parameter hematology analyzers and the compact XQ Series of automated multi-parameter hematology analyzers for 3-part white blood cell differentials in Japan. Regulatory approvals are currently being pursued in each country, and global sales will be rolled out sequentially. We will also continue evolving our product portfolio in the hematology field to help optimize laboratory operations according to regional characteristics and facility needs.」

「Against this backdrop, we have begun selling the next-generation flagship XR Series of automated multi-parameter hematology analyzers and the compact XQ Series of automated multi-parameter hematology analyzers for 3-part white blood cell differentials in Japan. Regulatory approvals are currently being pursued in each country, and global sales will be rolled out sequentially.」

「Against this backdrop, we have begun selling the next-generation flagship XR Series of automated multi-parameter hematology analyzers and the compact XQ Series of automated multi-parameter hematology analyzers for 3-part white blood cell differentials in Japan. We will develop global sales after obtaining regulatory approvals in each country.」

「Against this backdrop, we aim to continuously expand our product portfolio in the hematology field. We are selling the next-generation flagship XR Series of automated multi-parameter hematology analyzers and the compact XQ Series of automated multi-parameter hematology analyzers for 3-part white blood cell differentials in Japan, and will promote global sales after obtaining regulatory approvals in each country.」

「Against this backdrop, we launched the next-generation flagship XR Series of automated multi-parameter hematology analyzers and the compact XQ Series of automated multi-parameter hematology analyzers for 3-part white blood cell differentials in Japan, with the aim of continuously evolving our product portfolio in the hematology testing field. After obtaining regulatory approvals in each country, we will promote global sales and continue evolving our product portfolio in the hematology testing field to help optimize laboratory operations according to regional characteristics and facility needs.」

「July 2020: We obtained Japan's first marketing authorization for the XN-31 automated multi-parameter hematology analyzer as a Class III highly controlled medical device usable for malaria diagnosis. August 2020: We launched the CN-6500/CN-3500 fully automated blood coagulation analyzers, new products in the blood coagulation testing field.」

「Against this backdrop, we will launch the CN-6500/CN-3500 fully automated blood coagulation analyzers in the Japanese market, enabling an efficient testing workflow in the blood coagulation testing field. The system retains the features of our CN-6000/CN-3000 fully automated blood coagulation analyzers, including high productivity, reliability, operability and serviceability, while integrating an immunoassay unit based on chemiluminescence enzyme immunoassay, or CLEIA, the measurement principle used in our HISCL™-5000/HISCL™-800 fully automated immunoassay analyzers.」

「In the blood coagulation testing field, we aim to expand our market share by accelerating the adoption of the CN-6000/CN-3000 fully automated blood coagulation analyzers, partnering with Siemens, and expanding our proprietary reagent portfolio.」

「April 2019: The Automated Hematology Analyzer XN-31, a new product in the hematology testing field equipped with an automated function for measuring red blood cells infected with malaria parasites and other pathogens, obtained the CE mark as compliant with the European IVD Directive. The product is scheduled to be launched in Europe, followed by launches in Africa and Asia as regulatory approvals are obtained in each country.」

「April 2019: The Automated Hematology Analyzer XN-31, a new product in the hematology testing field equipped with an automated function for measuring red blood cells infected with malaria parasites and other pathogens, obtained the CE mark as compliant with the European IVD Directive. The product is scheduled to be launched in Europe, followed by launches in Africa and Asia as regulatory approvals are obtained in each country.」

「⑦ December 2018: We announced the launch of the Revohem FIX Synthetic Substrate coagulation factor IX assay kit, a new kit compatible with the CS-5100/CS-2500/CS-2400 and CS-2100i/CS-2000i/CS-1600 fully automated blood coagulation analyzers. Used to support the diagnosis and treatment of hemophilia B, this was the first coagulation factor IX assay kit for plasma based on the synthetic substrate method to be introduced to the Japanese market. ⑧ December 2018: We announced the launch of the CN-6000/CN-3000 fully automated blood coagulation analyzers, new products in the blood coagulation testing field offering improved productivity, reliability and operability.」

「With the aim of further expanding its share and business in the hematology testing field in the increasingly competitive Chinese market, we launched the XS-500ix, a product for the Chinese market in the XS Series of automated multi-parameter hematology analyzers, in September 2018. The product is manufactured at the company's Jinan plant in Jinan, Shandong Province, China, allowing it to be supplied in a form suited to local market characteristics while retaining the high quality and production efficiency developed through domestic instrument manufacturing.」

「The group will further strengthen its earnings capacity by expanding product lineups in the hematology, blood coagulation testing and urinalysis fields, expanding sales and services globally, and expanding its immunoassay business in Asia. To achieve its long-term management objectives, the group will promote personalized medicine by creating new testing and diagnostic technologies through the integration of its proprietary technologies with technologies acquired through open innovation.」

「We expanded the product lineup of the XN Series of automated multi-parameter hematology analyzers in the hematology testing field and launched the new XN Series of automated multi-parameter hematology analyzers, including the new SP-50 smear preparation system, comprising the XN-9100, XN-3100 and XN-1500, globally. The new XN Series reduces the required system installation space by making the conveyor line more compact, while the SP-50 has an installation footprint approximately 60% that of the previous model.」

「We launched the Revohem PT reagent for prothrombin time (PT), a key test item for monitoring anticoagulant therapy for conditions caused by thrombosis, including myocardial infarction and cerebral infarction, in Japan. We also launched the Revohem FVIII Synthetic Substrate quantitative coagulation factor VIII assay reagent, a new product in the blood coagulation testing field, in Japan.」

「We expanded the product lineup of the XN Series of automated multi-parameter hematology analyzers in the hematology testing field and launched the new XN Series of automated multi-parameter hematology analyzers, including the new SP-50 smear preparation system, comprising the XN-9100, XN-3100 and XN-1500, globally. The new XN Series reduces the required system installation space by making the conveyor line more compact, while the SP-50 has an installation footprint approximately 60% that of the previous model.」

「The group will further strengthen its earnings capacity by expanding product lineups in the hematology, blood coagulation testing and urinalysis fields, expanding sales and services globally, and expanding its immunoassay business in Asia. To achieve its long-term management objectives, the group will also make strategic investments in the development of highly competitive products using its proprietary technologies and in the execution of global business strategies.」

「We will pursue initiatives including expanding the product lineups in the hematology, coagulation and urinalysis fields, expanding sales and services globally, expanding the immunoassay business in Asia, and expanding the genetic testing business by leveraging our proprietary technologies.」